Melbourne, 23^rd November 2022: The field of proteomics is set to be revolutionised with the launch today of IonOpticks’Aurora Frontier that achieves more than 10,000 proteins per sample. This near-full proteome coverage, a depth previously considered unattainable, unlocks the potential for ground-breaking scientific discoveries in human health.

Proteomics provides a greater understanding of the complexity of life than other forms of in-depth biological research approaches, such as genomics, as it provides deeper insight into the structure and function of proteins and how they react within the cell in response to their environment.

At IonOpticks, Dr Jarrod Sandow, Chief Product Officer, has been at the forefront of developing technologies that help researchers push beyond the limits of existing biological research approaches and unlock deeper insight into the proteome. “We know that the limits of scientific discoveries are defined by the tools available. We developed this product to enhance the world of proteome analysis with greater precision than ever before, significantly amplifying possibilities for scientific discoveries,” says Dr Sandow. “The Aurora Frontier gives researchers the opportunity to understand the proteome at greater depths than mass spectrometry has ever achieved before, opening up possibilities of discoveries that could not have been accomplished with existing technologies,” Sandow continued.

Despite the awareness of the potential of proteomics, advancements in research have been held back by the lack of innovative technology available to drive progress in the field. The capabilities in mass spectrometry have improved significantly over the last decade, however, its true potential is only realised when paired with the best possible chromatographic column.

Frontier allows researchers to get as much as possible from their samples, which are often precious and very labour-intensive to generate. Having a deeper understanding of the proteome can help researchers better understand disease, define opportunities for early diagnosis, identify new targets and monitor outcomes for the benefit of therapy intervention.

“Together with the extended IonOpticks range and improved mass spectrometry capabilities, the technology that underpins proteomics research is now affordable, robust, reproducible, sensitive, easy to use and fast enough to allow the field of proteomics to flourish.” Dr Sandow continues.

Aurora Frontier is a 60cm nanoflow UHPLC packed emitter column and boasts class-leading performance using long sample gradients, enabling researchers to get more depth of coverage due to its unmatched peak capacity when compared to other nanoflow chromatography.

Studies show the product can produce more than 10,000 unique protein IDs, over 25 per cent more than the next highest performing commercially available column for single species samples.

IonOpticks’ columns are used for a broad range of applications within the field of biological and medical research including infectious diseases, drug discovery, cancer biology and Alzheimer’s disease, enabling scientists and clinicians to discover more from their samples and achieve data quality and deep proteome coverage on a whole new scale. IonOpticks developed Aurora Frontier to meet the demands of customers and mass spectrometry vendors who wanted better separation of samples to unlock the full potential of mass spectrometers. Frontier is part of IonOpticks’ Aurora Series and follows the launch of its Generation 3 product base which launched the highest-performing and most user-friendly UHPLC columns available.